Absolutely, see my post above. I believe NEU are now preparing for acquisition and conducting a PW P2 trial does not fit within this timeline (and would provide questionable additional value given 2591 has now already been proven in 2 synaptopathies and hopefully 3 soon). Any BP acquirer will have the optionality of pursuing PW as well as the "undisclosed indications" NEU is providing proof-of-principle evidence for.
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-143
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.42 |
Change
-0.720(3.25%) |
Mkt cap ! $2.829B | |||
| Open | High | Low | Value | Volume |
| $22.06 | $22.11 | $21.28 | $1.922M | 88.24K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29 | $21.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.43 | 48 | 3 |
View Market Depth
| Last trade - 10.36am 18/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |